![](https://investorshub.advfn.com/uicon/496411.png?cb=1505403973)
Thursday, January 05, 2023 2:19:39 PM
the Opioid Studies For Biel Have Been Posts Dozens Of Times.
And then tell Kelly to post them on the clinical evidence page of her website, because they're all conspicuous in their absence.
PLEASE don't paste any powerpoint slides or bar graphs or old quotes from Andy. CITE THE JOURNAL ARTICLE.
And don't cite any of Ilfeld's case studies. BIEL needs a clinical trial, not a Case Study.
And don't cite Ilfeld's current active ActiPatch Pilot study because (a) it's just a PILOT STUDY and (b) There aren't any endpoints, primary or secondary, regarding opioid use. The Primary endpoints are all about VAS scores (Likert scale), and only one secondary endpoint (#11, see link below) is about analgesics -- ALL analgesics, not just opioids.
https://clinicaltrials.gov/ct2/show/NCT05392803?cond=Phantom+Pain&locn=San+Diego&draw=2&rank=5
Ilfeld appears to be planning some opioid use endpoints in future trials. He hasn't started any of those yet.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM